scispace - formally typeset
R

Rakesh K. Jain

Researcher at Harvard University

Publications -  1528
Citations -  198912

Rakesh K. Jain is an academic researcher from Harvard University. The author has contributed to research in topics: Angiogenesis & Cancer. The author has an hindex of 200, co-authored 1467 publications receiving 177727 citations. Previous affiliations of Rakesh K. Jain include Government Medical College, Thiruvananthapuram & University of Oslo.

Papers
More filters
Journal ArticleDOI

Transport of molecules, particles, and cells in solid tumors.

TL;DR: This paradigm of analysis and synthesis has fostered a better understanding of physiological barriers in solid tumors and aided in the development of novel strategies to exploit and/or overcome these barriers for improved cancer detection and treatment.
Journal ArticleDOI

Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels

TL;DR: Losartan reduces solid stress in tumours resulting in increased vascular perfusion, thereby potentiating chemotherapy and reducing hypoxia in breast and pancreatic cancer models, suggesting that angiotensin inhibitors —inexpensive drugs with decades of safe use — could be rapidly repurposed as cancer therapeutics.
Journal ArticleDOI

Tissue engineering: creation of long-lasting blood vessels.

TL;DR: It is shown that a network of long-lasting blood vessels can be formed in mice by co-implantation of vascular endothelial cells and mesenchymal precursor cells, by-passing the need for risky genetic manipulations.
Journal ArticleDOI

Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood

TL;DR: The data offer a possible explanation for the antivascular effects of cytotoxic agents and suggest potential strategies for targeting the tumor vasculature.
Journal ArticleDOI

Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization

TL;DR: Anti-angiogenic treatments directly targeting angiogenic signaling pathways as well as indirectly modulating angiogenesis show normalization of tumor vasculature and microenvironment at least transiently in both preclinical and clinical settings.